Search research articles
Contact Us
Filters
Showing results (71-80 of 204) with videos related to
Page
of 21
Sort By:
Future Oncology (London, England)
|
March 7, 2019
Management of common adverse events related to first-line dacomitinib use in <i>EGFR</i> mutation-positive non-small-cell lung cancer: a pooled safety analysis
Qing Zhou, Yi-Long Wu, Jesus Corral, et al.
JTO Clinical and Research Reports
|
November 22, 2021
Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
Puja Shahrouki, Jay M Lee, Jonathan Barclay, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2011
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib
Matthias R Benz, Ken Herrmann, Franziska Walter, et al.
Scientific Reports
|
February 9, 2018
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
Manjima Dhar, Jessica Wong, James Che, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 9, 2018
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R Spigel, Craig Reynolds, David Waterhouse, et al.
Expert Opinion on Biological Therapy
|
September 22, 2016
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology
Cesare Gridelli, Paolo A Ascierto, Massimo C P Barberis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 29, 2013
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer
Hak Choy, Lee S Schwartzberg, Shaker R Dakhil, et al.
Computers in Biology and Medicine
|
January 26, 2015
Representing and extracting lung cancer study metadata: study objective and study design
Jean I Garcia-Gathright, Andrea Oh, Phillip A Abarca, et al.
Current Medical Research and Opinion
|
August 12, 2020
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancer
Kiyotaka Yoh, Shinji Atagi, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 18, 2012
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung
Martin J Edelman, Wael A Harb, Sridhar E Pal, et al.
Page
of 21
Search research articles
Search
Showing results (71-80 of 204) with videos related to
Sort By:
Page
of 21
Future Oncology (London, England)
|
March 7, 2019
Management of common adverse events related to first-line dacomitinib use in <i>EGFR</i> mutation-positive non-small-cell lung cancer: a pooled safety analysis
Qing Zhou, Yi-Long Wu, Jesus Corral, et al.
JTO Clinical and Research Reports
|
November 22, 2021
Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
Puja Shahrouki, Jay M Lee, Jonathan Barclay, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2011
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib
Matthias R Benz, Ken Herrmann, Franziska Walter, et al.
Scientific Reports
|
February 9, 2018
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
Manjima Dhar, Jessica Wong, James Che, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 9, 2018
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R Spigel, Craig Reynolds, David Waterhouse, et al.
Expert Opinion on Biological Therapy
|
September 22, 2016
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology
Cesare Gridelli, Paolo A Ascierto, Massimo C P Barberis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 29, 2013
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer
Hak Choy, Lee S Schwartzberg, Shaker R Dakhil, et al.
Computers in Biology and Medicine
|
January 26, 2015
Representing and extracting lung cancer study metadata: study objective and study design
Jean I Garcia-Gathright, Andrea Oh, Phillip A Abarca, et al.
Current Medical Research and Opinion
|
August 12, 2020
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancer
Kiyotaka Yoh, Shinji Atagi, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 18, 2012
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung
Martin J Edelman, Wael A Harb, Sridhar E Pal, et al.
Page
of 21